Pregabalin (Lyrica) and gabapentin (Neurontin) were originally classified as low-risk medications for neuropathic pain and epilepsy, but clinical evidence now shows that both produce dose-dependent euphoria, physical dependence with withdrawal syndrome, and patterns of misuse that mirror benzodiazepine addiction. Pregabalin has been reclassified as a controlled substance in the UK and several other jurisdictions. Gabapentin misuse is increasingly recognised in addiction treatment populations, particularly among individuals with concurrent opioid or benzodiazepine use disorders.
The Emerging Recognition
“Five years ago, gabapentinoids were considered safe alternatives to benzodiazepines. Today we see patients whose pregabalin dependence is as severe and as difficult to treat as any benzodiazepine case,” explains Dr. Ponlawat Pitsuwan, Physician, Phuket Island Rehab. “The delay in recognising this class of drugs as addictive follows the same pattern as benzodiazepines and opioids before them: initial prescribing enthusiasm, gradual accumulation of dependence cases, and eventual regulatory response. Patients who develop dependence during this recognition gap often feel dismissed because their medication was not supposed to be addictive.”
How Gabapentinoids Work
Pregabalin and gabapentin bind to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. By reducing calcium influx at presynaptic terminals, they decrease the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. This mechanism produces anxiolytic, analgesic, and anticonvulsant effects that are pharmacologically distinct from benzodiazepines (which act on GABA-A receptors).
At therapeutic doses, the anxiolytic and analgesic effects are clinically useful for neuropathic pain, generalised anxiety disorder, fibromyalgia, and as adjuncts in alcohol and benzodiazepine withdrawal. At supratherapeutic doses (typically 2 to 5 times the prescribed amount), particularly with pregabalin, users report a euphoria described as similar to a mild benzodiazepine or alcohol intoxication: warmth, relaxation, social disinhibition, and a “floating” sensation. This dose-dependent euphoric effect is the driver of recreational misuse.
Pregabalin has significantly higher bioavailability (90% versus gabapentin’s dose-dependent 30 to 60%) and more predictable absorption, which makes it more reliably euphoria-producing at higher doses and therefore more frequently misused. Gabapentin’s saturable absorption mechanism means that doubling the dose does not reliably double the blood level, making dose escalation for euphoria less predictable but not impossible, particularly when doses are staggered.
| Property | Pregabalin (Lyrica) | Gabapentin (Neurontin) |
|---|---|---|
| Bioavailability | ~90% (dose-independent) | 30-60% (dose-dependent, decreases at higher doses) |
| Onset of euphoric effects | 1-2 hours | 2-3 hours (variable) |
| Controlled substance status | Schedule V (US), Class C (UK), controlled in several countries | Not controlled federally (US); controlled in some US states and UK |
| Withdrawal syndrome | Anxiety, insomnia, nausea, sweating, seizures (rare) | Similar but generally milder; seizures documented |
| Common misuse population | Both standalone misuse and polysubstance users (opioid, benzodiazepine) | Primarily polysubstance users who use gabapentin to potentiate opioids |
The Polysubstance Connection
Gabapentinoid misuse is disproportionately prevalent among people with existing opioid or benzodiazepine use disorders. Gabapentin and pregabalin are used to potentiate opioid effects (increasing the perceived high), to manage withdrawal symptoms between opioid doses, and to enhance the sedative effects of benzodiazepines. In opioid substitution therapy populations (patients on methadone or buprenorphine), gabapentinoid misuse rates range from 15 to 40% in some studies.
This polysubstance pattern creates a clinical challenge because gabapentinoids may be prescribed legitimately for neuropathic pain or anxiety in the same patients who are at highest risk for misusing them. Clinical vigilance, including urine drug screening that specifically tests for gabapentinoids (not included in standard panels), prescription monitoring programme checks, and careful assessment of dosing patterns, is essential for identifying misuse in these populations.
The Withdrawal Syndrome
Gabapentinoid withdrawal, while generally less dangerous than benzodiazepine withdrawal, produces significant distress and can include seizures. Symptoms typically begin 12 to 48 hours after the last dose and include anxiety, insomnia, nausea, sweating, tachycardia, agitation, and confusion. Seizures have been documented in both pregabalin and gabapentin withdrawal, particularly after abrupt cessation of high doses.
The withdrawal is often not recognised as such because the symptoms closely resemble the conditions for which the medication was originally prescribed (anxiety, pain, insomnia). Patients and clinicians may interpret withdrawal symptoms as recurrence of the underlying disorder, leading to reinstatement rather than tapering. This perpetuates the dependence in the same way that benzodiazepine rebound anxiety perpetuates benzodiazepine dependence.
Safe discontinuation involves a gradual taper, typically reducing the dose by 10 to 25% every 1 to 2 weeks. The taper rate should be individualised based on duration of use, dose, and symptom response. For patients with concurrent alcohol or benzodiazepine dependence, gabapentinoid tapering is integrated into the overall withdrawal management plan rather than addressed in isolation.
When Substance Use Has Become More Than Occasional
Gabapentinoid dependence often develops invisibly because the medications were prescribed by a physician for a legitimate condition. The patient may not recognise dose escalation as problematic (“My pain is worse, so I take more”) or may not connect inter-dose anxiety to pharmacological withdrawal. The gradual nature of tolerance development means that what began as a therapeutic dose may have doubled or tripled over months without the patient framing this as drug escalation.
If you are taking significantly more pregabalin or gabapentin than prescribed, if you experience anxiety or restlessness between doses, if you have sought additional prescriptions or purchased the medication illicitly, or if you are using gabapentinoids to enhance the effects of other substances, these patterns indicate a dependent relationship that warrants clinical assessment. Prescription drug treatment at Phuket Island Rehab provides supervised tapering alongside therapeutic support for the conditions that gabapentinoids were managing, ensuring that the underlying pain, anxiety, or sleep disorder is addressed with non-dependent alternatives.
Summary
Pregabalin and gabapentin are increasingly recognised as substances with genuine dependence potential, particularly at supratherapeutic doses and in polysubstance use populations. Their dose-dependent euphoric effects, capacity to produce physical dependence with withdrawal syndrome, and frequent misuse alongside opioids and benzodiazepines place them firmly within the spectrum of addictive prescription medications. Clinical and regulatory recognition of this risk is evolving rapidly, and treatment approaches must address gabapentinoid dependence with the same pharmacological seriousness given to benzodiazepines.
“The gabapentinoid story is a reminder that the label ‘non-addictive’ applied to a new medication should always be treated as provisional until years of clinical experience confirm it,” notes Dr. Ponlawat Pitsuwan. “Patients who developed dependence on medications their doctors assured them were safe carry a justified sense of betrayal. Our clinical responsibility is to validate that experience while providing the evidence-based tapering and treatment that their dependence requires.”
Frequently Asked Questions
Is pregabalin addictive?
Yes. Clinical evidence supports that pregabalin produces dose-dependent euphoria, tolerance, physical dependence with withdrawal syndrome, and compulsive dose escalation in a subset of users. This is recognised by its classification as a controlled substance in the UK, US (Schedule V), and several other countries. Risk is highest at supratherapeutic doses and in individuals with a history of substance use disorders.
Why was gabapentin not initially considered addictive?
Gabapentin’s saturable absorption mechanism limits the dose-response relationship at higher doses, which was interpreted as reducing euphoria potential. Early clinical experience focused on therapeutic doses where dependence is uncommon. Recognition of misuse patterns emerged gradually as prescribing expanded beyond neurology into pain management and psychiatry, where patient populations with pre-existing substance use disorders were more prevalent.
Can gabapentinoid withdrawal cause seizures?
Yes. Seizures have been documented during both pregabalin and gabapentin withdrawal, particularly after abrupt cessation of high doses or prolonged use. While seizure risk is lower than with benzodiazepine withdrawal, it is sufficient to warrant gradual tapering rather than abrupt discontinuation. Medical supervision during discontinuation is recommended, especially for patients taking above-prescribed doses.
How do gabapentinoids interact with alcohol?
Both pregabalin and gabapentin enhance the sedative effects of alcohol. The combination increases cognitive impairment, reduces coordination, and can cause respiratory depression at high doses. For individuals with alcohol dependence, gabapentinoid use (whether prescribed or misused) creates a secondary dependence that complicates recovery. Treatment should address both substances.
Are gabapentinoids detected on standard drug tests?
No. Standard urine drug panels do not include gabapentin or pregabalin. Specific immunoassay or gas chromatography-mass spectrometry testing is required. This means that gabapentinoid misuse can occur undetected in treatment programmes, employment drug testing, and forensic settings unless specifically requested.
What alternatives exist for the conditions gabapentinoids treat?
For neuropathic pain: duloxetine (SNRI), amitriptyline (TCA), topical capsaicin, and nerve block procedures. For anxiety: SSRIs, buspirone, cognitive behavioural therapy. For fibromyalgia: duloxetine, exercise programmes, cognitive behavioural pain management. For epilepsy: multiple non-gabapentinoid anticonvulsants exist. The alternative choice depends on the specific condition and should be guided by a prescriber aware of the dependence risk.
Sources:
Evoy KE, et al. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs, 2021; 81(1): 125-156.
Bonnet U, Scherbaum N. How Addictive Are Gabapentin and Pregabalin? A Systematic Review. European Neuropsychopharmacology, 2017; 27(12): 1185-1215.
UK Advisory Council on the Misuse of Drugs. Pregabalin and Gabapentin Advice. gov.uk, 2016.
pregabalin · Lyrica · gabapentin · Neurontin · gabapentinoid · alpha-2-delta subunit · voltage-gated calcium channel · neuropathic pain · dose-dependent euphoria · physical dependence · withdrawal syndrome · seizure risk · polysubstance use · opioid potentiation · controlled substance · Schedule V · bioavailability · duloxetine · amitriptyline · fibromyalgia · medical taper · Dr. Ponlawat Pitsuwan · Phuket Island Rehab